Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen to Cut Costs of Instrumentation Division; Expects Drop in Q2 Revenues

NEW YORK, July 1 (GenomeWeb News) - Ciphergen Biosystems expects a significant drop in revenues for the second quarter and plans to cut costs in its instrumentation division, the company said yesterday.

 

Ciphergen estimates revenues of $10-11 million for the quarter ending yesterday, down from $14.3 million during the same period last year.

 

Bill Rich, the company's president and CEO, said in statement that "we will take steps to reduce operating expenses in our Biosystems Division more in line with a reduced revenue run rate." He also told GenomeWeb News that it is unclear yet whether the cost cutting will involve layoffs. More details will be announced during a webcast later this month.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.